Screener
Aurinia Pharmaceuticals AUPH Accrued sales rebates and fees
Accrued sales rebates and fees at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept auph:AccruedSalesRebateAndFeesCurrent.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued sales rebates and fees | $40,330 | $30,832 |
| Accrued payroll and related expenses | 11,842 | 18,869 |
| Accrued research and development expenses | 5,634 | 6,127 |
| Accrued sales and marketing expenses | 1,304 | 1,648 |
| Accrued corporate and excise taxes | 860 | 2,010 |
| Accrued other expenses | 4,142 | 7,135 |
| Total accrued expenses | $64,112 | $66,621 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's accrued sales rebates and fees?
- Aurinia Pharmaceuticals (AUPH) reported accrued sales rebates and fees of $40.33M in Q2 2026.
- How has Aurinia Pharmaceuticals's accrued sales rebates and fees changed year-over-year?
- Aurinia Pharmaceuticals's accrued sales rebates and fees increased by 61.3% year-over-year, from $25M to $40.33M.
- What does accrued sales rebates and fees mean?
- Accrued sales rebates and fees as reported by Aurinia Pharmaceuticals Inc.
Ask your AI about Aurinia Pharmaceuticals's accrued sales rebates and fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude